Chidinma Okogbue
Psychiatric/Mental Health · Grand Rapids, MINPI 1528798238
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 475 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,612, more than ten times the $197 reported in 2022. Among psychiatric/mental health clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 475 payments — averaging $13.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$1K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$641
- Neurocrine Biosciences, Inc.$581
- Johnson & Johnson$448
- Otsuka America Pharmaceutical, Inc.$430
- plus $2K from 11 others
What the payments were for
- Food & beverage$6,336100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 115 | $1,487 |
| AbbVie | 120 | $1,038 |
| Teva Pharmaceuticals USA, Inc. | 48 | $641 |
| Neurocrine Biosciences, Inc. | 38 | $581 |
| Johnson & Johnson | 23 | $448 |
| Otsuka America Pharmaceutical, Inc. | 24 | $430 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $428 |
| Alkermes, Inc. | 18 | $395 |
| Lundbeck LLC | 9 | $269 |
| Collegium Pharmaceutical, Inc. | 22 | $185 |
| Vanda Pharmaceuticals Inc. | 3 | $76 |
| Ironshore Pharmaceuticals Inc. | 4 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $71 |
| Corium, LLC | 3 | $68 |
| E.r. Squibb & Sons, L.L.C. | 3 | $65 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Indivior Inc. | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$144
How this compares
$6,336 in reported general payments places this provider in the 90th percentile of 638 psychiatric/mental health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 22 | $113,488 |
| LybalviOlanzapine/Samidorphan Malate | 20 | $31,184 |
| TrintellixVortioxetine Hydrobromide | 13 | $7,008 |
| Lamotrigine ErLamotrigine | 13 | $4,221 |
| Clozapine | 28 | $2,717 |
| Aripiprazole | 76 | $2,168 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $1,845 |
| Bupropion XlBupropion Hcl | 82 | $1,792 |
| Quetiapine Fumarate | 143 | $1,474 |
| Duloxetine Hcl | 62 | $1,386 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $1,265 |
| Buspirone Hcl | 77 | $1,239 |
| Hydroxyzine Pamoate | 69 | $940 |
| Sertraline Hcl | 78 | $903 |
| Lamotrigine | 52 | $891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $641 | $113,48822 claims |
| Alkermes, Inc.Lybalvi | $395 | $31,18420 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $71 | $7,00813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 638 psychiatric/mental health providers in Michigan.
Other psychiatric/mental health in Grand Rapids
- Iguelle BernardGrand Rapids$7K
- Amy StrattonGrand Rapids$7K
- Duren GutierrezSouthfield$207K
- Tamlynn EvansTraverse City$78K
- Shiba NixonClarkston$60K
- Amy AmesClinton Township$43K
- Cody ShinavierClarkston$41K
- Oksana LidkeBattle Creek$30K
- Jennifer Wims-MaddenPontiac$28K
- Jessica ShantzWarren$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.